Deep Track Capital LP Takes $16.44 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

Deep Track Capital LP bought a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,000,000 shares of the company's stock, valued at approximately $16,440,000. Deep Track Capital LP owned 1.87% of Upstream Bio at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Upstream Bio during the fourth quarter worth $25,000. US Bancorp DE acquired a new stake in Upstream Bio in the 4th quarter worth about $27,000. Legal & General Group Plc purchased a new stake in Upstream Bio during the 4th quarter worth approximately $28,000. Summit Investment Advisors Inc. acquired a new position in shares of Upstream Bio during the fourth quarter valued at approximately $30,000. Finally, Tower Research Capital LLC TRC purchased a new position in shares of Upstream Bio in the fourth quarter valued at approximately $47,000.

Upstream Bio Stock Performance

Shares of NASDAQ:UPB traded up $0.76 during trading on Monday, reaching $9.58. The stock had a trading volume of 75,262 shares, compared to its average volume of 326,497. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46. The business has a fifty day moving average price of $8.03 and a 200-day moving average price of $13.42.

Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. As a group, equities research analysts expect that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.